-
公开(公告)号：US20230045783A9
公开(公告)日：2023-02-09
申请号：US17468103
申请日：2021-09-07
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US20220056138A1
公开(公告)日：2022-02-24
申请号：US17519327
申请日：2021-11-04
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Christian Scheffold , Colin Hessel
IPC: C07K16/28 , A61P35/04 , A61K31/47 , A61K39/395 , A61K45/06
Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
-
公开(公告)号：US20220000857A1
公开(公告)日：2022-01-06
申请号：US17468103
申请日：2021-09-07
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US11141413B2
公开(公告)日：2021-10-12
申请号：US16093426
申请日：2017-04-17
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US20240350477A1
公开(公告)日：2024-10-24
申请号：US18359214
申请日：2023-07-26
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
CPC classification number: A61K31/47 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/16 , A61P35/00
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
Patent Agency Ranking
公开(公告)号：US20190352403A1
公开(公告)日：2019-11-21
申请号：US16479143
申请日：2018-01-19
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Christian Scheffold , Colin Hessel
IPC: C07K16/28 , A61K31/47 , A61K39/395 , A61K45/06 , A61P35/04
Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
-
公开(公告)号：US20190262330A1
公开(公告)日：2019-08-29
申请号：US16230267
申请日：2018-12-21
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Ann E. Borgman , Colin Hessel
Abstract: The present disclosure relates to a method of treating liver cancer, particularly hepatocellular carcinoma, using cabozantinib, a kinase inhibitor.
-
公开(公告)号：US20220401433A1
公开(公告)日：2022-12-22
申请号：US17888356
申请日：2022-08-15
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US11198731B2
公开(公告)日：2021-12-14
申请号：US16479143
申请日：2018-01-19
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Christian Scheffold , Colin Hessel
Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
-
公开(公告)号：US20190209547A1
公开(公告)日：2019-07-11
申请号：US16093426
申请日：2017-04-17
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
CPC classification number: A61K31/47 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/16 , A61P35/00
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.019 seconds)
